Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 66 entries
View as:

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Phase: N/A Priority: Normal
NCT ID: NCT04188379 Org: User:
Start: 12/16/19 End: 02/03/22 Due: 02/03/23

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT06298552 Org: User:
Start: 04/16/24 End: 07/23/27 Due: 07/23/28

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT06558279 Org: User:
Start: 09/18/24 End: 12/31/27 Due: 12/31/28

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

Phase: N/A Priority: Normal
NCT ID: NCT05633407 Org: User:
Start: 09/23/22 End: 04/18/24 Due: 04/18/25

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Phase: N/A Priority: Normal
NCT ID: NCT03669588 Org: User:
Start: 08/22/18 End: 04/06/20 Due: 04/06/21

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

Phase: N/A Priority: Normal
NCT ID: NCT05817669 Org: User:
Start: 04/04/23 End: 02/12/24 Due: 02/12/25

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Phase: N/A Priority: Normal
NCT ID: NCT06920004 Org: User:
Start: 05/31/25 End: 05/31/30 Due: 05/31/31

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

Phase: N/A Priority: Normal
NCT ID: NCT06307626 Org: User:
Start: 03/28/24 End: 10/31/27 Due: 10/31/28

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Phase: N/A Priority: Normal
NCT ID: NCT06503731 Org: User:
Start: 08/30/24 End: 09/30/27 Due: 09/30/28

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT06307613 Org: User:
Start: 03/27/24 End: 10/31/27 Due: 10/31/28

A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

Phase: N/A Priority: Normal
NCT ID: NCT06441682 Org: User:
Start: 10/23/24 End: 07/31/27 Due: 07/31/28

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06684847 Org: User:
Start: 01/15/25 End: 07/31/28 Due: 07/31/29

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Phase: N/A Priority: Normal
NCT ID: NCT05810961 Org: User:
Start: 02/20/23 End: 08/05/24 Due: 08/05/25

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age with Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT06392386 Org: User:
Start: 06/28/24 End: 09/30/26 Due: 09/30/27

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Phase: N/A Priority: Normal
NCT ID: NCT05927415 Org: User:
Start: 07/17/23 End: 06/12/24 Due: 06/12/25

A Study to Assess the Safety of ARGX-213 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT06968338 Org: User:
Start: 04/11/25 End: 01/06/26 Due: 01/06/27

Open Label Extension of Efgartigimod in Adults with Post-COVID-19 POTS

Phase: N/A Priority: Normal
NCT ID: NCT05918978 Org: User:
Start: 06/20/23 End: 08/15/24 Due: 08/15/25

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT04687072 Org: User:
Start: 12/16/20 End: 10/09/23 Due: 10/09/24

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05670704 Org: User:
Start: 02/21/23 End: 08/08/24 Due: 08/08/25

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

Phase: N/A Priority: Normal
NCT ID: NCT04777734 Org: User:
Start: - End: - Due: -

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy And/or Breastfeeding.

Phase: N/A Priority: Normal
NCT ID: NCT06299748 Org: User:
Start: 11/30/23 End: 12/31/33 Due: 12/31/34

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Phase: N/A Priority: Normal
NCT ID: NCT04598477 Org: User:
Start: 07/15/21 End: 03/25/24 Due: 03/25/25

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT05405361 Org: User:
Start: 01/18/23 End: 09/30/29 Due: 09/30/30

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013)

Phase: N/A Priority: Normal
NCT ID: NCT05810948 Org: User:
Start: 02/21/23 End: 09/30/25 Due: 09/30/26

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)

Phase: N/A Priority: Normal
NCT ID: NCT04598451 Org: User:
Start: 12/01/20 End: 08/22/23 Due: 08/22/24